tirzepatide news october 18 2025 Long-Term Safety of Tirzepatide: What Research and Experts Reveal Lilly hikes revenue forecasts on

Weeks 1-4: Initiation Phase Starting dose is low to minimize GI side effects Most patients notice reduced appetite within the first 1-2 weeks Mild nausea is common and typically improves within days Weight loss: 2-5 pounds (mostly water and initial caloric reduction) Key focus: Establish protein intake targets and begin resistance training if not already active Baseline DEXA scan and comprehensive bloodwork completed Months 2-3: Dose Escalation Dose increases every 4 weeks toward therapeutic range Appetite suppression becomes more consistent GI side effects may temporarily recur with each dose increase Weight loss: 1-2 pounds per week typical Patients often report improved energy, better sleep, reduced cravings Follow-up bloodwork to check metabolic markers Months 4-6: Therapeutic Phase Most patients have reached their maintenance dose Steady, consistent weight loss of 1-2 pounds per week Visible changes in body composition and clothing fit Metabolic markers (fasting glucose, triglycerides, HbA1c) typically improving Follow-up DEXA scan to verify fat loss vs

Its essential to discuss these parameters with a doctor to ensure the most effective and safe option is picked

JAMA Network Vaezi MF, Yang YX, Howden CW

Another point to be considered is the 17 trials with unreported pancreatic cancer events, from which we only received replies of 4 authors